Stephen Yip

List of Publications by Year in Descending Order

144 papers	6,396 citations	37 h-index	78 g-index
169 ext. papers	7,864 ext. citations	7.3 avg, IF	5.36 L-index

#	Paper	IF	Citations
144	Radiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab.. *Cureus*, **2022**, 14, e22159	1.2	
143	A platform for oncogenomic reporting and interpretation.. *Nature Communications*, **2022**, 13, 756	17.4	1
142	The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis.. *Current Oncology*, **2022**, 29, 2630-2643	2.8	0
141	Integrated proteomic analysis of low-grade gliomas reveals contributions of 1p-19q co-deletion to oligodendroglioma.. *Acta Neuropathologica Communications*, **2022**, 10, 70	7.3	0
140	Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury.. *Npj Precision Oncology*, **2021**, 5, 103	9.8	2
139	Protracted clinical course of an AFF1 fusion positive uterine smooth muscle tumor causing diagnostic confusion over a course of 15 years.. *Gynecologic Oncology Reports*, **2021**, 38, 100890	1.3	
138	Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care. *Journal of Community Genetics*, **2021**, 1	2.5	1
137	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. *Science Translational Medicine*, **2021**, 13, eabc0497	17.5	3
136	Histologic Correlates of Molecular Group 4 Pediatric Medulloblastoma: A Retrospective Canadian Review. *Pediatric and Developmental Pathology*, **2021**, 24, 309-317	2.2	1
135	MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy. *Lung Cancer*, **2021**, 154, 142-145	5.9	2
134	Loss of H3K27me3 in meningiomas. *Neuro-Oncology*, **2021**, 23, 1282-1291	1	7
133	Novel findings and expansion of phenotype in a mosaic RASopathy caused by somatic KRAS variants. *American Journal of Medical Genetics, Part A*, **2021**, 185, 2829-2845	2.5	5
132	Deep-learning based classification distinguishes sarcomatoid malignant mesotheliomas from benign spindle cell mesothelial proliferations. *Modern Pathology*, **2021**, 34, 2028-2035	9.8	2
131	RARE-15. THE MOLECULAR PROFILE OF SECONDARY MENINGIOMAS IN SURVIVORS OF CHILDHOOD NON-CENTRAL NERVOUS SYSTEM CANCERS. *Neuro-Oncology*, **2021**, 23, i43-i44	1	78
130	Clinical and cost outcomes following genomics-informed treatment for advanced cancers. *Cancer Medicine*, **2021**, 10, 5131-5140	4.8	3
129	G-quadruplexes mark alternative lengthening of telomeres. *NAR Cancer*, **2021**, 3, zcab031	5.2	3
128	Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic Cancers. *Clinical Cancer Research*, **2021**, 27, 522-531	12.9	4

127	Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. *Clinical Cancer Research*, **2021**, 27, 202-212	12.9	19
126	Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma. *Modern Pathology*, **2021**, 34, 1008-1016	9.8	8
125	Perivenular Enhancement Without Microbleeds Due to Amyloid Beta-Related Angiitis. *Neurohospitalist, The*, **2021**, 11, 267-269	1.1	
124	Matching methods in precision oncology: An introduction and illustrative example. *Molecular Genetics & Genomic Medicine*, **2021**, 9, e1554	2.3	3
123	Beyond BRCA? clinical utility of homologous recombination deficiency in gastrointestinal cancers.. *Journal of Clinical Oncology*, **2021**, 39, 472-472	2.2	
122	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients. *Current Oncology*, **2021**, 28, 346-366	2.8	9
121	A case series of pediatric survivors of anaplastic pleomorphic xanthoastrocytoma. *Neuro-Oncology Advances*, **2021**, 3, vdaa176	0.9	
120	NTRK2 Fusion driven pediatric glioblastoma: Identification of oncogenic Drivers via integrative Genome and transcriptome profiling. *Clinical Case Reports (discontinued)*, **2021**, 9, 1472-1477	0.7	2
119	Integrating Tumor Sequencing Into Clinical Practice for Patients With Mismatch Repair-Deficient Lynch Syndrome Spectrum Cancers. *Clinical and Translational Gastroenterology*, **2021**, 12, e00397	4.2	
118	Interpretable multimodal deep learning for real-time pan-tissue pan-disease pathology search on social media. *Modern Pathology*, **2020**, 33, 2169-2185	9.8	14
117	High-grade transformation of low-grade endometrial stromal sarcomas lacking YWHAE and BCOR genetic abnormalities. *Modern Pathology*, **2020**, 33, 1861-1870	9.8	9
116	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. *Cell Reports Medicine*, **2020**, 1,	18	11
115	Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing. *Genetics in Medicine*, **2020**, 22, 1892-1897	8.1	15
114	Making heads or tails - the emergence of capicua (CIC) as an important multifunctional tumour suppressor. *Journal of Pathology*, **2020**, 250, 532-540	9.4	11
113	Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic structural variant. *Journal of Physical Education and Sports Management*, **2020**, 6,	2.8	3
112	Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes.. *Nature Cancer*, **2020**, 1, 452-468	15.4	34
111	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. *Nature Medicine*, **2020**, 26, 720-731	50.5	60
110	Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma. *Histopathology*, **2020**, 76, 722-730	7.3	14

109	Establishing a Framework for the Clinical Translation of Germline Findings in Precision Oncology. *JNCI Cancer Spectrum*, **2020**, 4, pkaa045	4.6	0
108	Ependymoma and Chordoma. *Neurosurgery*, **2020**, 87, 860-870	3.2	2
107	Synthesis of diagnostic quality cancer pathology images by generative adversarial networks. *Journal of Pathology*, **2020**, 252, 178-188	9.4	15
106	Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer. *Breast Cancer Research and Treatment*, **2020**, 183, 525-547	4.4	5
105	Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC). *Journal of Medical Economics*, **2020**, 23, 1123-1129	2.4	7
104	TRIM25 promotes Capicua degradation independently of ERK in the absence of ATXN1L. *BMC Biology*, **2020**, 18, 154	7.3	1
103	EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes. *Translational Lung Cancer Research*, **2020**, 9, 1084-1092	4.4	1
102	Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer. *Pathology and Oncology Research*, **2020**, 26, 1385-1399	2.6	19
101	Finding a four-leaf clover-identifying long-term survivors in IDH-wildtype glioblastoma. *Neuro-Oncology*, **2019**, 21, 1352-1353	1	3
100	Imaging-Based 3-Dimensional Printing for Improved Maxillofacial Presurgical Planning: A Single Center Case Series. *Canadian Association of Radiologists Journal*, **2019**, 70, 74-82	3.9	7
99	Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in Wild-Type Pancreatic Ductal Adenocarcinoma. *Clinical Cancer Research*, **2019**, 25, 4674-4681	12.9	63
98	Application of a Neural Network Whole Transcriptome-Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers. *JAMA Network Open*, **2019**, 2, e192597	10.4	25
97	Pathology of Primary Brain Tumors Gliomas **2019**, 121-137		2
96	Base excision repair deficiency signatures implicate germline and somatic aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. *Journal of Physical Education and Sports Management*, **2019**, 5,	2.8	17
95	Rise of the Machines: Advances in Deep Learning for Cancer Diagnosis. *Trends in Cancer*, **2019**, 5, 157-169	12.5	69
94	Prognostic significance of human telomerase reverse transcriptase promoter region mutations C228T and C250T for overall survival in spinal chordomas. *Neuro-Oncology*, **2019**, 21, 1005-1015	1	11
93	Transcriptomic analysis of CIC and ATXN1L reveal a functional relationship exploited by cancer. *Oncogene*, **2019**, 38, 273-290	9.2	23
92	The pivotal role of sampling recurrent tumors in the precision care of patients with tumors of the central nervous system. *Journal of Physical Education and Sports Management*, **2019**, 5,	2.8	4

91	MYCN amplification drives an aggressive form of spinal ependymoma. *Acta Neuropathologica*, **2019**, 138, 1075-1089	14.3	51
90	Therapeutic Implication of Genomic Landscape of Adult Metastatic Sarcoma.. *JCO Precision Oncology*, **2019**, 3, 1-25	3.6	5
89	Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.. *Journal of Clinical Oncology*, **2019**, 37, e15753-e15753	2.2	1
88	Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.. *Journal of Clinical Oncology*, **2019**, 37, 273-273	2.2	
87	The whole genome landscape of adult metastatic sarcoma.. *Journal of Clinical Oncology*, **2019**, 37, 3137-3137	2.2	
86	Confirmation of germline variants identified by tumor testing: A population-based study.. *Journal of Clinical Oncology*, **2019**, 37, e13021-e13021	2.2	
85	Clinicopathologic Characterization of GREB1-rearranged Uterine Sarcomas With Variable Sex-Cord Differentiation. *American Journal of Surgical Pathology*, **2019**, 43, 928-942	6.7	22
84	Commentary: Radiological Characteristics and Natural History of Adult IDH-Wild-Type Astrocytomas With TERT Promoter Mutations. *Neurosurgery*, **2019**, 85, E457-E458	3.2	
83	Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer. *Journal of Physical Education and Sports Management*, **2019**, 5,	2.8	2
82	Molecular characterization of -amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. *Journal of Physical Education and Sports Management*, **2018**, 4,	2.8	9
81	Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making. *Journal of Physical Education and Sports Management* , **2018**, 4,	2.8	14
80	Case of Primary Central Nervous System Lymphoma Arising at Site of Remote Herpes Encephalitis. *World Neurosurgery*, **2018**, 113, 217-222	2.1	1
79	Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma. *Npj Precision Oncology*, **2018**, 2, 8	9.8	11
78	Machine learning classifies cancer. *Nature*, **2018**, 555, 446-447	50.4	36
77	Novel EPC1 gene fusions in endometrial stromal sarcoma. *Genes Chromosomes and Cancer*, **2018**, 57, 598-603	5	23
76	Temporal Dynamics of Genomic Alterations in a Germline-Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorouracil, Oxaliplatin, Leucovorin, and Irinotecan. *JCO Precision Oncology*, **2018**, 2,	3.6	0
75	Comparative RNA-Sequencing Analysis Benefits a Pediatric Patient With Relapsed Cancer. *JCO Precision Oncology*, **2018**, 2,	3.6	6
74	Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline :c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma. *Journal of Physical Education and Sports Management*, **2017**, 3,	2.8	6

73	Comparative transcriptome analysis of isogenic cell line models and primary cancers links capicua (CIC) loss to activation of the MAPK signalling cascade. *Journal of Pathology*, **2017**, 242, 206-220	9.4	22
72	The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers. *Molecular Genetics & Genomic Medicine*, **2017**, 5, 251-260	2.3	30
71	The driver landscape of sporadic chordoma. *Nature Communications*, **2017**, 8, 890	17.4	64
70	CSIG-12. EXPLORING THE FUNCTIONAL RELATIONSHIP BETWEEN CAPICUA (CIC) AND ATAXIN-1-LIKE (ATXN1L) IN GLIOMA. *Neuro-Oncology*, **2017**, 19, vi52-vi52	1	78
69	Detection and genomic characterization of a mammary-like adenocarcinoma. *Journal of Physical Education and Sports Management*, **2017**, 3,	2.8	8
68	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. *Acta Neuropathologica*, **2017**, 134, 705-714	14.3	114
67	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. *Npj Precision Oncology*, **2017**, 1, 5	9.8	37
66	Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer. *Clinical Cancer Research*, **2017**, 23, 7521-7530	12.9	82
65	Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. *Annals of Oncology*, **2017**, 28, 3092-3097	10.3	64
64	Epstein-Barr virus associated primary intracranial leiomyoma in a patient with human immunodeficiency virus **2017**, 36 (2017), 151-153		4
63	Whole genome and transcriptome sequencing of lung cancer: Options for personalized cancer treatment.. *Journal of Clinical Oncology*, **2017**, 35, e20567-e20567	2.2	1
62	Management of germline findings revealed throughout the course of tumor-normal whole genome sequencing in oncology.. *Journal of Clinical Oncology*, **2017**, 35, e13113-e13113	2.2	
61	Spinal column chordoma: prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival. *Neuro-Oncology*, **2017**, 19, 405-413	1	21
60	The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery. *Cell*, **2016**, 167, 1145-1149	56.2	232
59	ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors. *American Journal of Surgical Pathology*, **2016**, 40, 1051-61	6.7	108
58	High-resolution myelin water imaging in post-mortem multiple sclerosis spinal cord: A case report. *Multiple Sclerosis Journal*, **2016**, 22, 1485-1489	5	26
57	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. *Cancer Cell*, **2016**, 30, 891-908	24.3	135
56	Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer. *Annals of Oncology*, **2016**, 27, 801-6	10.3	27

55	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. *Journal of Histochemistry and Cytochemistry*, **2016**, 64, 587-600	3.4	24
54	Paternal uniparental disomy 11p15.5 in the pancreatic nodule of an infant with Costello syndrome: Shared mechanism for hyperinsulinemic hypoglycemia in neonates with Costello and Beckwith-Wiedemann syndrome and somatic loss of heterozygosity in Costello syndrome driving clonal expansion. *American Journal of Medical Genetics, Part A*, **2015**, 170, 559-64	2.5	9
53	Fatal congenital hypertrophic cardiomyopathy and a pancreatic nodule morphologically identical to focal lesion of congenital hyperinsulinism in an infant with costello syndrome: case report and review of the literature. *Pediatric and Developmental Pathology*, **2015**, 18, 237-44	2.2	12
52	The role of resection alone in select children with intracranial ependymoma: the Canadian Pediatric Brain Tumour Consortium experience. *Childs Nervous System*, **2015**, 31, 57-65	1.7	15
51	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. *Lancet Oncology, The*, **2015**, 16, 569-82	21.7	117
50	Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. *BMC Cancer*, **2015**, 15, 32	4.8	28
49	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. *Journal of Molecular Diagnostics*, **2015**, 17, 661-8	5.1	22
48	35-Year-Old Man with Lytic Skull Lesion. Langerhans Cell Histiocytosis (LCH). *Brain Pathology*, **2015**, 25, 367-8	6	
47	Microcystic Stromal Tumor: A Distinctive Ovarian Sex Cord-Stromal Neoplasm Characterized by FOXL2, SF-1, WT-1, Cyclin D1, and β-catenin Nuclear Expression and CTNNB1 Mutations. *American Journal of Surgical Pathology*, **2015**, 39, 1420-6	6.7	53
46	Novel targeted therapies in chordoma: an update. *Therapeutics and Clinical Risk Management*, **2015**, 11, 873-83	2.9	48
45	Deep sequencing identifies IDH1 R132S mutation in adult medulloblastoma. *Journal of Clinical Oncology*, **2015**, 33, e27-31	2.2	17
44	Integrative genomic analysis of ghost cell odontogenic carcinoma. *Oral Oncology*, **2015**, 51, e71-5	4.4	14
43	Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. *Journal of Physical Education and Sports Management*, **2015**, 1, a000570	2.8	75
42	Oligodendroglial Tumors. *Molecular Pathology Library*, **2015**, 105-120		
41	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. *Clinical Cancer Research*, **2015**, 21, 3307-17	12.9	176
40	EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study. *Cancer*, **2015**, 121, 1499-507	6.4	27
39	Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing. *PLoS ONE*, **2015**, 10, e0119689	3.7	32
38	Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement. *Modern Pathology*, **2014**, 27, 751-7	9.8	56

37	Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. *Nature Genetics*, **2014**, 46, 457-461	36.1	340
36	Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. *Neuro-Oncology*, **2014**, 16, 173-8	1	22
35	Somatic mosaicism for the p.His1047Arg mutation in PIK3CA in a girl with mesenteric lipomatosis. *American Journal of Medical Genetics, Part A*, **2014**, 164A, 2360-4	2.5	12
34	Diagnostic value of next-generation sequencing in an unusual sphenoid tumor. *Oncologist*, **2014**, 19, 623-30	5.7	17
33	Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. *BMC Cancer*, **2014**, 14, 982	4.8	21
32	Oncogenic codon 13 NRAS mutation in a primary mesenchymal brain neoplasm and nevus of a child with neurocutaneous melanosis. *Acta Neuropathologica Communications*, **2014**, 2, 140	7.3	16
31	Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. *Oncotarget*, **2014**, 5, 7960-79	3.3	28
30	Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children. *Cancer Research*, **2013**, 73, 6734-44	10.1	70
29	Array CGH in brain tumors. *Methods in Molecular Biology*, **2013**, 973, 325-38	1.4	3
28	Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. *Cell*, **2013**, 152, 1065-76	56.2	174
27	Cribriform neuroepithelial tumor or atypical teratoid/rhabdoid tumor?. *Journal of Neurosurgery: Pediatrics*, **2013**, 11, 486-8	2.1	1
26	Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. *Journal of Pathology*, **2013**, 231, 21-34	9.4	292
25	Converging paths to progress for skull base chordoma: Review of current therapy and future molecular targets. *Surgical Neurology International*, **2013**, 4, 72	1	12
24	Nucleic acid quantity and quality from paraffin blocks: defining optimal fixation, processing and DNA/RNA extraction techniques. *Experimental and Molecular Pathology*, **2012**, 92, 33-43	4.4	85
23	Atypical teratoid rhabdoid tumors (ATRTs): the British Columbia's Children's Hospital's experience, 1986-2006. *Brain Pathology*, **2012**, 22, 625-35	6	19
22	Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. *Journal of Pathology*, **2012**, 226, 7-16	9.4	226
21	Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. *Stem Cells*, **2012**, 30, 1064-75	5.8	53
20	DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma. *Annals of Neurology*, **2012**, 71, 845-9	9.4	21

19	Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. *Neuro-Oncology*, **2012**, 14, 132-44	1	165
18	Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. *Journal of the National Cancer Institute*, **2012**, 104, 42-55	9.7	83
17	Possible differentiation of cerebral glioblastoma into pleomorphic xanthoastrocytoma: an unusual case in an infant. *Journal of Neurosurgery: Pediatrics*, **2012**, 9, 517-23	2.1	14
16	Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. *Oncotarget*, **2012**, 3, 1112-23	3.3	103
15	Low-grade fibromyxoid sarcoma of the perineum with heterotopic ossification: case report and review of the literature. *Human Pathology*, **2011**, 42, 1804-9	3.7	18
14	Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. *Oncogene*, **2010**, 29, 3185-95	9.2	63
13	ARID1A mutations in endometriosis-associated ovarian carcinomas. *New England Journal of Medicine*, **2010**, 363, 1532-43	59.2	1208
12	Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. *Lancet Neurology, The*, **2010**, 9, 717-26	24.1	216
11	MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. *Clinical Cancer Research*, **2009**, 15, 4622-9	12.9	291
10	Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. *Journal of Neuropathology and Experimental Neurology*, **2008**, 67, 1-15	3.1	70
9	Stem-cell based therapies for brain tumors. *Current Opinion in Molecular Therapeutics*, **2008**, 10, 334-42		14
8	Neural stem cells as novel cancer therapeutic vehicles. *European Journal of Cancer*, **2006**, 42, 1298-308	7.5	39
7	Neural stem cell biology may be well suited for improving brain tumor therapies. *Cancer Journal (Sudbury, Mass)*, **2003**, 9, 189-204	2.2	51
6	Reduced xenograft rejection in rat striatum after pretransplant photodynamic therapy of murine neural xenografts. *Journal of Neurosurgery*, **2000**, 92, 127-31	3.2	9
5	Photosensitizing potencies of the structural analogues of benzoporphyrin derivative in different biological test systems. *Photomedicine and Laser Surgery*, **1996**, 14, 335-41		14
4	Selective elimination of malignant stem cells using photosensitizers followed by light treatment. *Stem Cells*, **1995**, 13, 336-43	5.8	11
3	Mouse skin photosensitization with benzoporphyrin derivatives and Photofrin: macroscopic and microscopic evaluation. *Photochemistry and Photobiology*, **1991**, 53, 281-6	3.6	48
2	Interpretable multimodal deep learning for real-time pan-tissue pan-disease pathology search on social media		1

1 Loss of CIC promotes mitotic dysregulation and chromosome segregation defects 1